Cargando…
Agreement between chromogenic in situ hybridisation (CISH) and FISH in the determination of HER2 status in breast cancer
Determination of the HER2/neu (HER2) status in breast carcinoma has become necessary for the selection of breast cancer patients for trastuzumab therapy. Amplification of the gene analysed by fluorescence in situ hybridisation (FISH) or overexpression of the protein determined by immunohistochemistr...
Autores principales: | Arnould, L, Denoux, Y, MacGrogan, G, Penault-Llorca, F, Fiche, M, Treilleux, I, Mathieu, M C, Vincent-Salomon, A, Vilain, M O, Couturier, J |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2003
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2377115/ https://www.ncbi.nlm.nih.gov/pubmed/12771927 http://dx.doi.org/10.1038/sj.bjc.6600943 |
Ejemplares similares
-
Chromogenic in situ hybridisation for the assessment of HER2 status in breast cancer: an international validation ring study
por: van de Vijver, Marc, et al.
Publicado: (2007) -
Comparison of Chromogenic In Situ Hybridisation with Fluorescence In Situ Hybridisation and Immunohistochemistry for the Assessment of Her-2/neu Oncogene in Archival Material of Breast Carcinoma
por: Pothos, Alexios, et al.
Publicado: (2008) -
Monosomy 3 by chromogenic in situ hybridization (CISH) in Iranian patients with uveal melanoma
por: Naseripour, Masood, et al.
Publicado: (2015) -
Evaluating HER2 Gene Amplification Using Chromogenic In Situ Hybridization (CISH) Method In Comparison To Immunohistochemistry Method in Breast Carcinoma
por: Atabati, Hadi, et al.
Publicado: (2018) -
Chromogenic in situ hybridization (CISH): a novel alternative in screening archival breast cancer tissue samples for HER-2/neu status
por: Madrid, Manuelito A, et al.
Publicado: (2004)